CHU de Quebec-Universite Laval: Prostatic Neoplasms trials

The registry lists 14 Prostatic Neoplasms studies with CHU de Quebec-Universite Laval as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.RecruitingNCT07483658Not applicable
• A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.RecruitingNCT06052683Not applicable
• A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical TherapyNot yet recruitingNCT05896371Phase 1/2
• Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.RecruitingNCT05786742Not applicable
• Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.SuspendedNCT05820633Not applicable
• Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.CompletedNCT04655365Phase 2
• Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET ScanningActive, not recruitingNCT04009967Phase 2
• Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.Active, not recruitingNCT03753334Phase 2
• Diet, Physical Activity and Related Candidate Biomarkers in Relation to Prostate Cancer Risk (BIOCaPPE)Active, not recruitingNCT03383016
• HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate CancerCompletedNCT02628041Phase 2
• Effects of EPA on Prostate Cancer Cells Proliferation and Quality of LifeActive, not recruitingNCT02333435Phase 2
• Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard TreatmentActive, not recruitingNCT01851018Not applicable
• Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its ProgressionActive, not recruitingNCT01653925Not applicable
• Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer PatientsTerminatedNCT00714376Phase 2